GLP1R and neoplasm: Yang et al. [54] conducted a comprehensive analysis of the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, spanning from 2004 to 2021, to investigate the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tumor-related adverse events.